Fulgent Genetics, Inc.

For the period ended Mar 31, 2026. Filed May 1, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 1, 2026

FLGT$26.15+10.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except par value data)

	March 31, 2026	December 31, 2025
(unaudited)
Assets
Current assets
Cash and cash equivalents	$23,399	$50,193
Marketable securities	252,903	285,884
Trade accounts receivable, net of allowance for credit losses of $21,420 as of March 31, 2026, and $21,411 as of December 31, 2025	69,277	84,762
Prepaid income taxes	109,165	107,099
Other current assets	24,298	22,552
Total current assets	479,042	550,490
Marketable securities, long-term	328,287	369,269
Fixed assets, net	116,344	112,549
In-process research & development	68,490	68,490
Other intangible assets, net	85,499	64,791
Goodwill	53,731	25,080
Other long-term assets	24,976	22,856
Total assets	$1,156,369	$1,213,525
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$21,125	$18,654
Accrued liabilities	34,901	34,057
Customer deposit	30,619	28,145
Contract liabilities	3,007	3,635
Notes payable, current	482	476
Total current liabilities	90,134	84,967
Deferred tax liabilities	6,982	6,936
Unrecognized tax benefits	5,727	7,283
Other long-term liabilities	9,372	7,624
Total liabilities	112,215	106,810
Commitments and Contingencies (Note 8)
Stockholders’ equity
Common stock, $0.0001 par value per share, 50,000 shares authorized, 34,870 shares issued and 28,851 shares outstanding as of March 31, 2026, and 34,501 shares issued and 31,081 shares outstanding as of December 31, 2025	4	3
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding as of March 31, 2026, and December 31, 2025	—	—
Additional paid-in capital	540,141	574,520
Accumulated other comprehensive income	4,536	7,512
Retained earnings	505,128	529,954
Total Fulgent stockholders’ equity	1,049,809	1,111,989
Noncontrolling interest	(5,655)	(5,274)
Total stockholders’ equity	1,044,154	1,106,715
Total liabilities and stockholders’ equity	$1,156,369	$1,213,525

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.